MCID: MCR088
MIFTS: 57

Microscopic Polyangiitis

Categories: Rare diseases, Neuronal diseases, Cardiovascular diseases, Nephrological diseases, Respiratory diseases, Bone diseases

Aliases & Classifications for Microscopic Polyangiitis

MalaCards integrated aliases for Microscopic Polyangiitis:

Name: Microscopic Polyangiitis 53 59 37
Microscopic Polyarteritis 59 73
Micropolyangiitis 59
Mpa 59

Characteristics:

Orphanet epidemiological data:

59
microscopic polyangiitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Germany),1-9/1000000 (Norway),1-9/100000 (United Kingdom),1-9/100000 (Germany),1-9/100000 (Australia),1-9/100000 (Japan),1-9/100000 (Kuwait),1-9/1000000 (Canada),1-9/100000 (Greece),1-9/1000000 (Lithuania),1-9/100000 (Sweden); Age of onset: Adult; Age of death: adult;

Classifications:



Summaries for Microscopic Polyangiitis

NIH Rare Diseases : 53 Microscopic polyangiitis (MPA) is a disorder that causes blood vessel inflammation (vasculitis), which can lead to organ damage. The kidneys, lungs, nerves, skin, and joints are the most commonly affected areas of the body. MPA is diagnosed in people of all ages, all ethnicities, and both genders. The cause of this disorder is unknown.

MalaCards based summary : Microscopic Polyangiitis, also known as microscopic polyarteritis, is related to anca-associated vasculitis and wegener granulomatosis. An important gene associated with Microscopic Polyangiitis is MPO (Myeloperoxidase), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs alemtuzumab and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and lung, and related phenotypes are renal insufficiency and sinusitis

Wikipedia : 76 Microscopic polyangiitis is an ill-defined autoimmune disease characterized by a systemic, pauci-immune,... more...

Related Diseases for Microscopic Polyangiitis

Diseases related to Microscopic Polyangiitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 278)
# Related Disease Score Top Affiliating Genes
1 anca-associated vasculitis 32.0 HLA-DRB1 MPO TNF
2 wegener granulomatosis 30.3 IL10 MPO TNF
3 churg-strauss syndrome 30.3 IL10 MPO TNF
4 prostatitis 30.0 IL10 TNF
5 central nervous system vasculitis 30.0 HLA-DRB1 TNF
6 endocarditis 29.9 IL10 TNF
7 pneumonia 29.6 IL10 MPO TNF
8 lung disease 29.6 IL10 MPO TNF
9 chlamydia 29.5 IL10 TNF
10 gastrointestinal system disease 29.2 IL10 MPO TNF
11 mixed connective tissue disease 29.2 HLA-DRB1 IL10 TNF
12 connective tissue disease 29.1 HLA-DRB1 IL10 TNF
13 arthritis 29.1 HLA-DRB1 IL10 TNF
14 takayasu arteritis 29.0 HLA-B HLA-DRB1 TNF
15 cytomegalovirus infection 28.5 IL10 KIR3DL1 TNF
16 systemic lupus erythematosus 28.4 HLA-DRB1 IL10 MPO TNF
17 asthma 28.4 HLA-DRB1 IL10 MPO TNF
18 graft-versus-host disease 28.3 HLA-B HLA-DRB1 IL10 TNF
19 rheumatoid arthritis 28.0 HLA-B HLA-DRB1 IL10 TNF
20 vasculitis 11.4
21 autoimmune inner ear disease 10.5 MPO TNF
22 juvenile myasthenia gravis 10.4 HLA-DRB1 IL10
23 beryllium disease 10.4 HLA-DRB1 TNF
24 autoimmune pancreatitis 10.4 HLA-DRB1 TNF
25 chronic beryllium disease 10.4 HLA-DRB1 TNF
26 pleural disease 10.4 MPO TNF
27 proctitis 10.4 MPO TNF
28 lichen sclerosus 10.4 HLA-DRB1 TNF
29 ileitis 10.4 MPO TNF
30 actinic prurigo 10.4 HLA-DRB1 TNF
31 sympathetic ophthalmia 10.4 HLA-DRB1 TNF
32 polyarteritis nodosa, childhood-onset 10.4
33 polyarteritis nodosa 10.4
34 suppurative cholangitis 10.4 MPO TNF
35 microscopic colitis 10.4 HLA-DRB1 TNF
36 rheumatoid vasculitis 10.4 HLA-DRB1 TNF
37 discoid lupus erythematosus 10.4 HLA-DRB1 IL10
38 pleurisy 10.4 MPO TNF
39 cystic echinococcosis 10.4 HLA-DRB1 IL10
40 peanut allergy 10.4 HLA-DRB1 IL10
41 oligoarticular juvenile idiopathic arthritis 10.4 HLA-DRB1 TNF
42 punctate inner choroidopathy 10.4 IL10 TNF
43 tropical endomyocardial fibrosis 10.3 IL10 TNF
44 multifocal choroiditis 10.3 IL10 TNF
45 palindromic rheumatism 10.3 HLA-DRB1 TNF
46 tungiasis 10.3 IL10 TNF
47 endomyocardial fibrosis 10.3 IL10 TNF
48 rheumatic fever 10.3 HLA-DRB1 TNF
49 transient hypogammaglobulinemia 10.3 IL10 TNF
50 choroiditis 10.3 IL10 TNF

Graphical network of the top 20 diseases related to Microscopic Polyangiitis:



Diseases related to Microscopic Polyangiitis

Symptoms & Phenotypes for Microscopic Polyangiitis

Human phenotypes related to Microscopic Polyangiitis:

59 32 (show all 37)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal insufficiency 59 32 hallmark (90%) Very frequent (99-80%) HP:0000083
2 sinusitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000246
3 epistaxis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000421
4 uveitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000554
5 hematuria 59 32 hallmark (90%) Very frequent (99-80%) HP:0000790
6 cutis marmorata 59 32 occasional (7.5%) Occasional (29-5%) HP:0000965
7 skin rash 59 32 hallmark (90%) Very frequent (99-80%) HP:0000988
8 arthritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001369
9 subcutaneous nodule 59 32 occasional (7.5%) Occasional (29-5%) HP:0001482
10 congestive heart failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0001635
11 pericarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001701
12 pancreatitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001733
13 subcutaneous hemorrhage 59 32 frequent (33%) Frequent (79-30%) HP:0001933
14 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
15 diarrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002014
16 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
17 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
18 hemoptysis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002105
19 gastrointestinal hemorrhage 59 32 frequent (33%) Frequent (79-30%) HP:0002239
20 peritonitis 59 32 frequent (33%) Frequent (79-30%) HP:0002586
21 vasculitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002633
22 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
23 autoimmunity 59 32 hallmark (90%) Very frequent (99-80%) HP:0002960
24 myalgia 59 32 frequent (33%) Frequent (79-30%) HP:0003326
25 paresthesia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003401
26 venous thrombosis 59 32 frequent (33%) Frequent (79-30%) HP:0004936
27 gastrointestinal infarctions 59 32 frequent (33%) Frequent (79-30%) HP:0005244
28 abnormality of the retinal vasculature 59 32 occasional (7.5%) Occasional (29-5%) HP:0008046
29 erythema 59 32 hallmark (90%) Very frequent (99-80%) HP:0010783
30 arrhythmia 59 32 occasional (7.5%) Occasional (29-5%) HP:0011675
31 oliguria 59 32 hallmark (90%) Very frequent (99-80%) HP:0100520
32 episcleritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100534
33 gangrene 59 32 occasional (7.5%) Occasional (29-5%) HP:0100758
34 glomerulopathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0100820
35 skin ulcer 59 32 frequent (33%) Frequent (79-30%) HP:0200042
36 peripheral neuropathy 59 Occasional (29-5%)
37 increased inflammatory response 59 Very frequent (99-80%)

Drugs & Therapeutics for Microscopic Polyangiitis

Drugs for Microscopic Polyangiitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
alemtuzumab Approved, Investigational Phase 4 216503-57-0
2
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 50-18-0, 6055-19-2 2907
4
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
5
Azathioprine Approved Phase 4,Phase 3,Phase 2 446-86-6 2265
6
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
7
rituximab Approved Phase 4,Phase 2,Phase 3,Not Applicable 174722-31-7 10201696
8
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
9
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
10
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 53-03-2 5865
11
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
13 Alkylating Agents Phase 4,Phase 3,Phase 2
14 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
15 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
17 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Vitamin B Complex Phase 4,Phase 3,Phase 2
19 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
21 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 Antimetabolites Phase 4,Phase 3,Phase 2
25 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
26 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2
27 Prednisolone acetate Phase 4,Phase 2,Phase 3
28 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
29 Methylprednisolone acetate Phase 4,Phase 2,Phase 3
30 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 3
31 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Not Applicable
32 Neuroprotective Agents Phase 4,Phase 2,Phase 3
33 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
34 Hormones Phase 4,Phase 2,Phase 3,Not Applicable
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
36 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
37 Prednisolone hemisuccinate Phase 4,Phase 2,Phase 3
38 Prednisolone phosphate Phase 4,Phase 2,Phase 3
39 Antiemetics Phase 4,Phase 2,Phase 3
40 Protective Agents Phase 4,Phase 2,Phase 3
41 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
42 Autonomic Agents Phase 4,Phase 2,Phase 3
43 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
44 Tin Fluorides Phase 4
45 Folate Nutraceutical Phase 4,Phase 3,Phase 2
46 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2
47
belimumab Approved Phase 3 356547-88-1 5957 10451420
48
Dexchlorpheniramine Experimental, Investigational Phase 3 25523-97-1 33036
49 Antibodies Phase 3,Phase 2,Not Applicable
50 Immunoglobulins Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
2 Alemtuzumab for ANCA Associated Refractory Vasculitis Unknown status NCT01405807 Phase 4 Alemtuzumab
3 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
4 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
5 Low-dose Glucocorticoid Vasculitis Induction Study Recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
6 A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis Suspended NCT02115997 Phase 4 Methylprednisolone;Prednisone;Rituximab
7 Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA) Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
8 WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
9 Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
10 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
11 Belimumab in Remission of VASculitis Completed NCT01663623 Phase 3 Azathioprine
12 Efficacy Study of Two Treatments in the Remission of Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
13 Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis Completed NCT00987389 Phase 3 Glucocorticoids
14 Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
15 Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
16 Rituximab Vasculitis Maintenance Study Active, not recruiting NCT01697267 Phase 3 Azathioprine
17 Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab Active, not recruiting NCT02433522 Phase 3 rituximab;Placebo
18 Intravenous Immunoglobulin After Relapse in Vasculitis Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
19 Plasma Exchange for Renal Vasculitis Terminated NCT01408836 Phase 2, Phase 3 Intravenous methyl prednisolone;Methyl prednisolone
20 IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis Terminated NCT00307645 Phase 3 Cyclophosphamide;Mycophenolate mofetil;Azathioprine;Prednisone (and methylprednisolone)
21 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
22 Anti-Cytokine Therapy for Vasculitis Completed NCT00753103 Phase 2 Cyclophosphamide;Prednisolone;Azathioprine;Mycophenolate mofetil;Methylprednisolone
23 Steroids and Methotrexate to Treat Systemic Vasculitis Completed NCT00001256 Phase 2 prednisone and methotrexate
24 Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies Recruiting NCT03385668 Phase 2 Pirfenidone
25 A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Active, not recruiting NCT01750697 Phase 2 Rituximab
26 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Not yet recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
27 Abatacept in ANCA Associated Vasculitis Terminated NCT00482066 Phase 2 Abatacept (Orencia)
28 BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis Withdrawn NCT01598857 Phase 2 Blisibimod;Placebo
29 CellCept in p-ANCA Vasculitis Completed NCT00405860 Phase 1 CellCept (mycophenolate mofetil)
30 Hematopoietic Stem Cell Support in Vasculitis Terminated NCT00278512 Phase 1
31 Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis Unknown status NCT02126098
32 PRO Development for ANCA Associated Vasculitis Unknown status NCT01729624
33 An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Completed NCT01613599 Rituximab
34 RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Completed NCT00307593 Not Applicable Infliximab;Rituximab
35 Educational Needs of Patients With Systemic Vasculitis Completed NCT02190929
36 Vasculitis Illness Perception (VIP) Study Completed NCT02190916
37 The ANCA Vasculitis Questionnaire (AAV-PRO©) Completed NCT02507024
38 Journey of Patients With Vasculitis From First Symptom to Diagnosis Completed NCT03410290
39 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
40 Impact of Vasculitis on Employment and Income Completed NCT02476292
41 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
42 Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis Recruiting NCT00315393
43 Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis Recruiting NCT02474888
44 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Recruiting NCT01066208
45 Pediatric Vasculitis Initiative Recruiting NCT02006134
46 One-Time DNA Study for Vasculitis Recruiting NCT01241305
47 VCRC Tissue Repository Recruiting NCT02967068
48 Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Recruiting NCT03004326
49 Vasculitis Pregnancy Registry Recruiting NCT02593565
50 Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) Active, not recruiting NCT01862068

Search NIH Clinical Center for Microscopic Polyangiitis

Genetic Tests for Microscopic Polyangiitis

Anatomical Context for Microscopic Polyangiitis

MalaCards organs/tissues related to Microscopic Polyangiitis:

41
Skin, Neutrophil, Lung, Kidney, Bone, Heart, Liver

Publications for Microscopic Polyangiitis

Articles related to Microscopic Polyangiitis:

(show top 50) (show all 424)
# Title Authors Year
1
A case of microscopic polyangiitis presenting with acute spinal subdural hemorrhage. ( 29971213 )
2018
2
Microscopic polyangiitis necrotizing glomerulonephritis associated with pregnancy: case with a 20-year clinical course and review of the literature. ( 29869147 )
2018
3
Microscopic polyangiitis presented with biopsy-confirmed pleuritis. ( 29927196 )
2018
4
Costs of Disease Relapses Among Individuals with Granulomatosis, with Polyangiitis, or Microscopic Polyangiitis in the United States. ( 29470835 )
2018
5
Necrosis of the gastrocnemius muscle in microscopic polyangiitis. ( 29374653 )
2018
6
Tuberculosis and Microscopic Polyangiitis. A Rare Combination. ( 29798821 )
2018
7
Contrast Enhanced Computed Tomography Revealed Gallbladder Hemorrhage Due to Active Vasculitis in a Patient With Microscopic Polyangiitis. ( 29561470 )
2018
8
Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis. ( 29621352 )
2018
9
Mean platelet volume can estimate the current vasculitis activity of microscopic polyangiitis. ( 29556749 )
2018
10
Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A<sub>2</sub> receptor in membranous nephropathy-lesions: report of two patients with microscopic polyangiitis. ( 29792176 )
2018
11
The evaluation of mean platelet volume in microscopic polyangiitis: methodological drawbacks. ( 29974185 )
2018
12
Chorea and Calcifications: Atypical Presentation of Microscopic Polyangiitis. ( 29976382 )
2018
13
Frequency, Diagnosis, Treatment, and Outcome of Gastrointestinal Disease in Granulomatosis with Polyangiitis and Microscopic Polyangiitis. ( 29419474 )
2018
14
Ruptured renal artery in microscopic polyangiitis: a case report and literature review. ( 29951966 )
2018
15
From fibrosis to diagnosis: a paediatric case of microscopic polyangiitis and review of the literature. ( 29294176 )
2018
16
Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review. ( 28733791 )
2017
17
IgM Antibodies to Proteinase 3 in Granulomatosis with Polyangiitis and Microscopic Polyangiitis. ( 28076879 )
2017
18
Prediction of response to remission induction therapy by gene expression profiling of peripheral blood in Japanese patients with microscopic polyangiitis. ( 28569178 )
2017
19
Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. ( 28905856 )
2017
20
Phlebectasia in a finger in a case of microscopic polyangiitis with peripheral polyneuropathy. ( 28838824 )
2017
21
Noninfective endocarditis in microscopic polyangiitis: Report of a case with a successful response to immunosuppressive therapy. ( 28822626 )
2017
22
The influence of the Great East Japan earthquake on microscopic polyangiitis: A retrospective observational study. ( 28498830 )
2017
23
Microscopic polyangiitis: Atypical presentation with extensive small bowel necrosis, diffuse alveolar hemorrhage, and renal failure. ( 28348948 )
2017
24
A Case of Microscopic Polyangiitis with Subarachnoid Hemorrhage and Cardiovascular Complications. ( 29142188 )
2017
25
A case of inclusion body myositis complicated by microscopic polyangiitis. ( 28726537 )
2017
26
Not Every Case of Temporal Arteritis Is Giant Cell Arteritis. Microscopic Polyangiitis Involving the Temporal Artery: A Case Report and Review of the Literature. ( 29293114 )
2017
27
Silicosis, then microscopic polyangiitis-antineutrophil cytoplasmic antibodies-associated vasculitis may be work-related disease in patients with silicosis. ( 29264045 )
2017
28
Gallbladder bleeding associated with microscopic polyangiitis: a case report. ( 28852465 )
2017
29
Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis with Polyangiitis, Microscopic Polyangiitis or Polyarteritis Nodosa without Poor Prognosis Factors A Randomized-Controlled Trial. ( 28678392 )
2017
30
Differential Expression of Toll-Like Receptor Signaling Pathway Is Associated with Microscopic Polyangiitis in Peripheral Blood Neutrophils. ( 28375762 )
2017
31
Myeloperoxidase/HLA Class II Complexes Recognized by Autoantibodies in Microscopic Polyangiitis. ( 28575531 )
2017
32
Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: an uncommon adverse effect? ( 29165307 )
2017
33
Remission Induction Therapy with Rituximab for Microscopic Polyangiitis: A Feasibility Study. ( 28539536 )
2017
34
Distinct pathogenesis in nonsystemic vasculitic neuropathy and microscopic polyangiitis. ( 29082297 )
2017
35
Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. ( 28422001 )
2017
36
Microscopic polyangiitis with dermatomyositis. ( 29308288 )
2017
37
Elevated serum levels of immunoglobulin A correlate with the possibility of readmission in patients with microscopic polyangiitis. ( 28616269 )
2017
38
A tale of two vasculitides: biopsy-proven giant cell arteritis followed by the independent development of renal-limited microscopic polyangiitis. ( 28432167 )
2017
39
Concurrent Double Fungal Infections of the Skin Caused by Phialemoniopsis endophytica and Exophiala jeanselmei in a Patient with Microscopic Polyangiitis. ( 28654130 )
2017
40
The effect and possible clinical efficacy of in vivo inhibition of neutrophil extracellular traps by blockade of PI3K-gamma on the pathogenesis of microscopic polyangiitis. ( 28880680 )
2017
41
Severe microscopic polyangiitis with unilateral vocal cord paralysis as initial manifestation. ( 28559644 )
2017
42
Development of intracerebral hemorrhage in the short-term clinical course of a patient with microscopic polyangiitis without neurological symptoms at diagnosis: an autopsy case. ( 28508972 )
2016
43
Predictive factors for mortality in elderly Japanese patients with severe microscopic polyangiitis: A retrospective single-center study. ( 27400379 )
2016
44
Ultra-Wide-Field Fluorescein Angiography in Microscopic Polyangiitis. ( 27872779 )
2016
45
Presence of Citrullinated Histone H3-Positive Neutrophils in Microscopic Polyangiitis from the Early Phase: An Autopsy Proven Case. ( 27427341 )
2016
46
[Combined pulmonary fibrosis and emphysema associated with microscopic polyangiitis]. ( 26346417 )
2016
47
Paraneoplastic microscopic polyangiitis presenting after thymectomy. ( 27222874 )
2016
48
Microscopic polyangiitis with crescentic glomerulonephritis initially presenting as acute pancreatitis. ( 26864299 )
2016
49
Pediatric case of microscopic polyangiitis with skin manifestations resembling vesiculobullous type erythema elevatum diutinum with immunoglobulin A antineutrophil cytoplasmic antibody. ( 27097593 )
2016
50
Central nervous system vasculitis in pediatric microscopic polyangiitis: A case report and review of literature. ( 27156236 )
2016

Variations for Microscopic Polyangiitis

Expression for Microscopic Polyangiitis

Search GEO for disease gene expression data for Microscopic Polyangiitis.

Pathways for Microscopic Polyangiitis

Pathways related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.53 HLA-B HLA-DRB1 IL10 KIR3DL1 MPO TNF
2
Show member pathways
13.02 HLA-B HLA-DRB1 IL10 TNF
3
Show member pathways
12.49 HLA-B HLA-DRB1 TNF
4
Show member pathways
12.32 HLA-B IL10 TNF
5
Show member pathways
12.28 IL10 MPO TNF
6 12.25 IL10 MPO TNF
7
Show member pathways
12.19 HLA-B KIR3DL1 TNF
8
Show member pathways
12.09 HLA-DRB1 IL10 TNF
9
Show member pathways
12.09 HLA-B HLA-DRB1 IL10 KIR3DL1 TNF
10 12.06 HLA-B HLA-DRB1 TNF
11 11.91 HLA-B HLA-DRB1 IL10
12
Show member pathways
11.85 HLA-DRB1 IL10 TNF
13 11.8 HLA-DRB1 IL10 TNF
14 11.61 HLA-B HLA-DRB1 MPO
15 11.5 IL10 TNF
16 11.48 IL10 TNF
17 11.4 IL10 MPO TNF
18 11.35 HLA-DRB1 IL10
19 11.28 IL10 TNF
20 11.27 IL10 TNF
21 11.26 MPO TNF
22 11.07 IL10 TNF
23 11.05 IL10 TNF
24 10.53 MPO TNF
25 10.28 HLA-DRB1 IL10 TNF

GO Terms for Microscopic Polyangiitis

Cellular components related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ER to Golgi transport vesicle membrane GO:0012507 8.96 HLA-B HLA-DRB1
2 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.62 HLA-B HLA-DRB1

Biological processes related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.58 IL10 MPO TNF
2 interferon-gamma-mediated signaling pathway GO:0060333 9.56 HLA-B HLA-DRB1
3 response to glucocorticoid GO:0051384 9.55 IL10 TNF
4 antigen processing and presentation GO:0019882 9.54 HLA-B HLA-DRB1
5 negative regulation of T cell proliferation GO:0042130 9.52 HLA-DRB1 IL10
6 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.51 IL10 TNF
7 negative regulation of mitotic cell cycle GO:0045930 9.49 IL10 TNF
8 positive regulation of cytokine secretion GO:0050715 9.48 IL10 TNF
9 negative regulation of interleukin-6 production GO:0032715 9.46 IL10 TNF
10 negative regulation of interferon-gamma production GO:0032689 9.43 HLA-DRB1 IL10
11 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.37 IL10 TNF
12 immune response GO:0006955 9.35 HLA-B HLA-DRB1 IL10 KIR3DL1 TNF
13 endothelial cell apoptotic process GO:0072577 9.32 IL10 TNF
14 negative regulation of cytokine secretion involved in immune response GO:0002740 9.26 IL10 TNF
15 receptor biosynthetic process GO:0032800 9.16 IL10 TNF
16 negative regulation of growth of symbiont in host GO:0044130 8.8 IL10 MPO TNF

Molecular functions related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.62 HLA-B HLA-DRB1

Sources for Microscopic Polyangiitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....